Autor: "Morgan, Todd M." - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune Phenotype.
Autorzy:: Farha M; Department of Medical Education, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Nallandhighal S; Department of Urology, Michigan Medicine, Ann Arbor, MI 48109, USA.
Vince R; Department of Urology, Michigan Medicine, Ann Arbor, MI 48109, USA.
Cotta B; Department of Urology, Michigan Medicine, Ann Arbor, MI 48109, USA.
Stangl-Kremser J; Department of Urology, Michigan Medicine, Ann Arbor, MI 48109, USA.; Department of Urology, Medical University of Vienna, 1090 Vienna, Austria.
Triner D; Department of Urology, Michigan Medicine, Ann Arbor, MI 48109, USA.
Morgan TM; Department of Urology, Michigan Medicine, Ann Arbor, MI 48109, USA.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Palapattu GS; Department of Medical Education, University of Michigan Medical School, Ann Arbor, MI 48109, USA.; Department of Urology, Michigan Medicine, Ann Arbor, MI 48109, USA.; Department of Urology, Medical University of Vienna, 1090 Vienna, Austria.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Cieslik M; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.; Department of Pathology, Michigan Medicine, Ann Arbor, MI 48109, USA.; Michigan Center for Translational Pathology, Michigan Medicine, Ann Arbor, MI 48109, USA.
Vaishampayan U; Department of Medical Education, University of Michigan Medical School, Ann Arbor, MI 48109, USA.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.; Department of Medicine, Michigan Medicine, Ann Arbor, MI 48109, USA.
Udager AM; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.; Department of Pathology, Michigan Medicine, Ann Arbor, MI 48109, USA.; Michigan Center for Translational Pathology, Michigan Medicine, Ann Arbor, MI 48109, USA.
Salami SS; Department of Medical Education, University of Michigan Medical School, Ann Arbor, MI 48109, USA.; Department of Urology, Michigan Medicine, Ann Arbor, MI 48109, USA.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.; Michigan Center for Translational Pathology, Michigan Medicine, Ann Arbor, MI 48109, USA.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2023 Nov 22; Vol. 15 (23). Date of Electronic Publication: 2023 Nov 22.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomy.
Autorzy:: Ho MD; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Black AJ; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Zargar H; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.; Department of Urology, Western Health, Melbourne, Australia.
Fairey AS; USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, United States.; University of Alberta, Edmonton, AB, Canada.
Mertens LS; Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Dinney CP; Department of Urology, MD Anderson Cancer Center, Houston, TX, United States.
Mir MC; Department of Urology, Fundacio Instituto Valenciano de Oncologia, Valencia, Spain.
Krabbe LM; Department of Urology, University of Münster, Münster, Germany.
Cookson MS; Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, OK, United States.
Jacobsen NE; University of Alberta, Edmonton, AB, Canada.
Montgomery JS; Department of Urology, University of Michigan Health System, Ann Arbor, MI, United States.
Yu EY; Department of Medicine, Division of Hematology/Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seattle, WA, United States.
Xylinas E; Department of Urology, Weill Cornell Medical College, Presbyterian Hospital, New York, NY, United States.
Kassouf W; Department of Surgery (Division of Urology), McGill University Health Centre, Montreal, QC, Canada.
Dall'Era MA; Department of Urology, University of California at Davis, Davis Medical Center, Sacramento, CA, United States.
Vasdev N; Department of Urology, Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Stevenage, United Kingdom.; Department of Urology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.
Sridhar SS; Princess Margaret Cancer Centre, Toronto, ON, Canada.
McGrath JS; Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, United Kingdom.
Aning J; Department of Urology, Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Stevenage, United Kingdom.; Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, United Kingdom.
Holzbeierlein JM; Department of Urology, University of Kansas Medical Center, Kansas City, KS, United States.
Thorpe AC; Department of Urology, Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Stevenage, United Kingdom.
Shariat SF; Department of Urology, Weill Cornell Medical College, Presbyterian Hospital, New York, NY, United States.; Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
Wright JL; Department of Urology, University of Washington, Seattle, WA, United States.
Morgan TM; Department of Urology, University of California at Davis, Davis Medical Center, Sacramento, CA, United States.
Bivalacqua TJ; Department of Urology, University of Pennsylvania, Philadelphia, PA, United States.
North S; Cross Cancer Institute, Edmonton, AB, Canada.
Barocas DA; Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, United States.
Lotan Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Grivas P; Department of Medicine, Division of Hematology/Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seattle, WA, United States.
Stephenson AJ; Department of Urology, Rush University, Chicago, IL, United States.
Shah JB; Department of Urology, Stanford University, Palo Alto, CA, United States.
van Rhijn BW; Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Daneshmand S; USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, United States.
Spiess PE; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
Black PC; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.; Pokaż więcej
Źródło:: Canadian Urological Association journal = Journal de l'Association des urologues du Canada [Can Urol Assoc J] 2023 Oct; Vol. 17 (10), pp. 301-309.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Characterization of Intercalated Cell Markers KIT and LINC01187 in Chromophobe Renal Cell Carcinoma and Other Renal Neoplasms.
Autorzy:: Mannan R; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Wang X; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Bawa PS; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Zhang Y; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Skala SL; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Chinnaiyan AK; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Dagar A; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Wang L; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Zelenka-Wang SB; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
McMurry LM; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Daniel N; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Cao X; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.; Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.; Howard Hughes Medical Institute, Ann Arbor, MI, USA.
Sangoi AR; Department of Pathology, El Camino Hospital, Mountain View, CA, USA.
Gupta S; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Vaishampayan UN; Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.; Department of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.
Hafez KS; Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
Morgan TM; Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
Spratt DE; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Tretiakova MS; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Argani P; Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA.
Chinnaiyan AM; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.; Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.; Howard Hughes Medical Institute, Ann Arbor, MI, USA.; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
Dhanasekaran SM; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Mehra R; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.; Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.; Pokaż więcej
Źródło:: International journal of surgical pathology [Int J Surg Pathol] 2023 Sep; Vol. 31 (6), pp. 1027-1040. Date of Electronic Publication: 2022 Oct 16.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Renal Cell*/diagnosis
Carcinoma, Renal Cell*/genetics
Carcinoma, Renal Cell*/pathology
Kidney Neoplasms*/diagnosis
Kidney Neoplasms*/genetics
Kidney Neoplasms*/pathology
Adenoma, Oxyphilic*/diagnosis
Adenoma, Oxyphilic*/pathology
Humans ; Follow-Up Studies ; Biomarkers, Tumor/metabolism ; RNA ; Diagnosis, Differential

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study.
Autorzy:: Schenk JM; Cancer Prevention Program, Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Liu M; Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Neuhouser ML; Cancer Prevention Program, Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Newcomb LF; Cancer Prevention Program, Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Urology, University of Washington, Seattle, Washington, USA.
Zheng Y; Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Zhu K; Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Brooks JD; Department of Urology, Stanford University, Stanford, California, USA.
Carroll PR; Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA.
Dash A; Veterans Affairs, Puget Sound, Seattle, Washington, USA.
Ellis WJ; Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Filson CP; Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA.; Winship Cancer Institute, Emory Healthcare, Atlanta, Georgia, USA.
Gleave ME; Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, USA.
Liss M; University of Texas Health Sciences Center, San Antonio, Texas, USA.
Martin FM; Department of Urology, Eastern Virginia Medical School, Virginia Beach, Virginia, USA.
Morgan TM; Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.
Wagner AA; Division of Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Lin DW; Cancer Prevention Program, Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Urology, University of Washington, Seattle, Washington, USA.; Pokaż więcej
Źródło:: Nutrition and cancer [Nutr Cancer] 2023; Vol. 75 (2), pp. 618-626. Date of Electronic Publication: 2022 Nov 07.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:: Prostatic Neoplasms*/pathology
Diet, Mediterranean*
Male ; Humans ; Prostate/pathology ; Neoplasm Grading ; Watchful Waiting/methods ; Prospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance.
Autorzy:: Brady L; Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Newcomb LF; Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Urology, University of Washington, Seattle, Washington, USA.
Zhu K; Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Zheng Y; Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Boyer H; Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Urology, University of Washington, Seattle, Washington, USA.
Sarkar N; Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
McKenney JK; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Brooks JD; Department of Urology, Stanford University, Stanford, California, USA.
Carroll PR; Department of Urology, University of California, San Francisco, California, USA.
Dash A; VA Puget Sound Health Care Systems, Seattle, WA, USA.
Ellis WJ; Department of Urology, University of Washington, Seattle, Washington, USA.
Filson CP; Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA.; Winship Cancer Institute, Emory Healthcare, Atlanta, Georgia, USA.
Gleave ME; Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Liss MA; Department of Urology, University of Texas Health Sciences Center, San Antonio, Texas, USA.
Martin F; Department of Urology, Eastern Virginia Medical School, Virginia Beach, Virginia, USA.
Morgan TM; Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.
Thompson IM; CHRISTUS Medical Center Hospital, San Antonio, Texas, USA.
Wagner AA; Division of Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Pritchard CC; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Lin DW; Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Urology, University of Washington, Seattle, Washington, USA.
Nelson PS; Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Urology, University of Washington, Seattle, Washington, USA.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2022 Nov; Vol. 11 (22), pp. 4332-4340. Date of Electronic Publication: 2022 Apr 25.
Typ publikacji:: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Germ-Line Mutation*
Prostatic Neoplasms*/pathology
Male ; Humans ; Watchful Waiting ; Retrospective Studies ; Genes, BRCA2 ; Genetic Predisposition to Disease

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer.
Autorzy:: Dadhania V; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Gonzalez D; Department of Pathology and Laboratory Medicine, Jackson Memorial Hospital, Miami, FL, USA.
Yousif M; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Department of Pathology, Vanderbilt University Medical Center, Nashville, TN, USA.
Cheng J; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Morgan TM; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
Spratt DE; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Reichert ZR; Department of Medical Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.
Mannan R; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Wang X; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Chinnaiyan A; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Cao X; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Dhanasekaran SM; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Chinnaiyan AM; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.; Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.; Howard Hughes Medical Institute, Ann Arbor, MI, USA.
Pantanowitz L; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.
Mehra R; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. .; Michigan Center for Translational Pathology, Ann Arbor, MI, USA. .; Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2022 May 05; Vol. 22 (1), pp. 494. Date of Electronic Publication: 2022 May 05.
Typ publikacji:: Journal Article
MeSH Terms:: Adenocarcinoma*/diagnosis
Adenocarcinoma*/genetics
Adenocarcinoma*/pathology
Prostatic Neoplasms*/pathology
Artificial Intelligence ; Gene Fusion ; Humans ; In Situ Hybridization, Fluorescence ; Male ; Oncogene Proteins, Fusion/genetics ; Transcriptional Regulator ERG/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Autorzy:: Reichert ZR; Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Kasputis T; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
Nallandhighal S; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
Abusamra SM; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
Kasputis A; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
Haruray S; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
Wang Y; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
Williams S; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
Singhal U; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA.; Department of Urology, Mayo Clinic, Rochester, MN 55901, USA.
Alva A; Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI 48109, USA.
Cackowski FC; Division of Medical Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.
Caram MEV; Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Palmbos PL; Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Yentz SE; Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.; Lieutenant Colonel Charles S. Kettles VA Medical Center, Ann Arbor, MI 48105, USA.
Smith DC; Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Alumkal JJ; Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
Morgan TM; Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2021 Dec 21; Vol. 23 (1). Date of Electronic Publication: 2021 Dec 21.
Typ publikacji:: Journal Article
MeSH Terms:: Drug Resistance, Neoplasm*
Biomarkers, Tumor/*genetics
Gene Expression Profiling/*methods
Neoplastic Cells, Circulating/*chemistry
Prostatic Neoplasms/*genetics
Androgen Antagonists/pharmacology ; Androgen Antagonists/therapeutic use ; Antigens, Neoplasm/genetics ; Desmoglein 2/genetics ; Humans ; Kallikreins/genetics ; Male ; Midkine/genetics ; Multiplex Polymerase Chain Reaction ; Precision Medicine ; Prognosis ; Prospective Studies ; Prostate-Specific Antigen/genetics ; Prostatic Neoplasms/drug therapy ; Receptors, Androgen/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.
Autorzy:: Soria F; Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy.
Black PC; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Fairey AS; University of Alberta, Edmonton, AB, Canada.
Cookson MS; Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, OK, USA.
Yu EY; Department of Medicine, Division of Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Kassouf W; Department of Surgery (Division of Urology), McGill University Health Center, Montreal, Canada.
Dall'Era MA; Department of Urology, Davis Medical Center, University of California at Davis, Sacramento, CA, USA.
Sridhar SS; Princess Margaret Hospital, Toronto, ON, Canada.
McGrath JS; Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, UK.
Wright JL; Department of Urology, University of Washington, Seattle, WA, USA.
Thorpe AC; Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK.
Morgan TM; Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA.
Daneshmand S; USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA.
Holzbeierlein JM; Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA.
Bivalacqua TJ; Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD, USA.
North S; Cross Cancer Institute, Edmonton, AB, Canada.; Department of Oncology, University of Alberta, Alberta, AB, Canada.
Barocas DA; Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Lotan Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Grivas P; Department of Medicine, Division of Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Stephenson AJ; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Shah JB; Department of Urology, Stanford University School of Medicine, Stanford, CA, USA.; Department of Urology, MD Anderson Cancer Center, Houston, TX, USA.
van Rhijn BW; Department of Urology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Spiess PE; Department of Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Shariat SF; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Department of Urology, Weill Cornell Medical College, Presbyterian Hospital, New York, NY, USA.; Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Gontero P; Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy.; Pokaż więcej
Źródło:: BJU international [BJU Int] 2021 Jul; Vol. 128 (1), pp. 79-87. Date of Electronic Publication: 2020 Nov 21.
Typ publikacji:: Comparative Study; Journal Article; Multicenter Study
MeSH Terms:: Cystectomy*/methods
Neoadjuvant Therapy*
Urinary Bladder Neoplasms/*drug therapy
Urinary Bladder Neoplasms/*surgery
Aged ; Cohort Studies ; Combined Modality Therapy ; Female ; Humans ; Hydronephrosis ; Male ; Middle Aged ; Neoplasm Staging ; Propensity Score ; Retrospective Studies ; Treatment Outcome ; Urinary Bladder Neoplasms/pathology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
Autorzy:: D'Andrea D; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Matin S; Department of Urology, MD Anderson Cancer Center, Houston, TX, USA.
Black PC; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Petros FG; Department of Urology and Kidney Transplant, Eleanor N. Dana Cancer Center, The University of Toledo Medical Center, Toledo, OH, USA.
Zargar H; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.; Department of Urology, Western Health, Melbourne, Vic., Australia.
Dinney CP; Department of Urology, MD Anderson Cancer Center, Houston, TX, USA.
Cookson MS; Department of Urology, Center and The Stephenson Cancer Center, The University of Oklahoma Health Sciences, Oklahoma City, OK, USA.
Kassouf W; Division of Urology, Department of Surgery, McGill University Health Center, Montreal, QC, Canada.
Dall'Era MA; Department of Urology, Davis Medical Center, University of California at Davis, Sacramento, CA, USA.
McGrath JS; Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA.
Wright JL; Department of Urology, University of Washington, Seattle, WA, USA.
Thorpe AC; Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK.
Morgan TM; Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA.
Holzbeierlein JM; Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA.
Bivalacqua TJ; Department of Urology, The Johns Hopkins School of Medicine, The James Buchanan Brady Urological Institute, Baltimore, MD, USA.
Sridhar SS; Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada.
North S; Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Barocas DA; Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Lotan Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Stephenson AJ; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
van Rhijn BW; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Spiess PE; Department of Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Daneshmand S; Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Shariat SF; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Departments of Urology, Weill Cornell Medical College, New York, NY, USA.; Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republic.; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.; Department of Urology, University of Jordan, Amman, Jordan.; European Association of Urology Research Foundation, Arnhem, The Netherlands.; Pokaż więcej
Źródło:: BJU international [BJU Int] 2021 May; Vol. 127 (5), pp. 528-537. Date of Electronic Publication: 2020 Oct 14.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Transitional Cell/*therapy
Kidney Neoplasms/*therapy
Ureteral Neoplasms/*therapy
Urinary Bladder Neoplasms/*therapy
Aged ; Carcinoma, Transitional Cell/pathology ; Cisplatin/therapeutic use ; Comparative Effectiveness Research ; Cystectomy ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Doxorubicin/therapeutic use ; Female ; Humans ; Kidney Neoplasms/pathology ; Male ; Methotrexate/therapeutic use ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Nephroureterectomy ; Proportional Hazards Models ; Retrospective Studies ; Survival Rate ; Treatment Outcome ; Ureteral Neoplasms/pathology ; Urinary Bladder Neoplasms/pathology ; Vinblastine/therapeutic use ; Gemcitabine
SCR Protocol:: M-VAC protocol

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Comparison of biopsy under-sampling and annual progression using hidden markov models to learn from prostate cancer active surveillance studies.
Autorzy:: Li W; Department of Industrial and Operations Engineering, University of Michigan, Ann Arbor, MI, USA.
Denton BT; Department of Industrial and Operations Engineering, University of Michigan, Ann Arbor, MI, USA.; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Nieboer D; Department of Urology, Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
Carroll PR; Department of Urology, UCSF - Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Roobol MJ; Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Morgan TM; Department of Urology, University of Michigan, Ann Arbor, MI, USA.; Pokaż więcej
Corporate Authors:: Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium
Źródło:: Cancer medicine [Cancer Med] 2020 Dec; Vol. 9 (24), pp. 9611-9619. Date of Electronic Publication: 2020 Nov 06.
Typ publikacji:: Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:: Early Detection of Cancer/*methods
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/*pathology
Watchful Waiting/*methods
Aged ; Biopsy ; Cohort Studies ; Databases, Factual ; Disease Progression ; Humans ; Male ; Markov Chains ; Middle Aged ; Models, Statistical ; Neoplasm Grading ; Prostatic Neoplasms/blood ; Risk Assessment/methods

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Clinicopathological characterisation of renal cell carcinoma in young adults: a contemporary update and review of literature.
Autorzy:: Abdulfatah E; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Kennedy JM; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Hafez K; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
Davenport MS; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.; Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, USA.
Xiao H; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Weizer AZ; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
Palapattu GS; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.; Department of Urology, Medical University of Vienna, Vienna, Austria.
Morgan TM; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
Mannan R; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Wang XM; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Dhanasekaran SM; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
Kaffenberger SD; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
Spratt DE; Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.
Kunju L; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Wu A; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Lew M; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Udager AM; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.; Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.
Chinnaiyan AM; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.; Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.; Howard Hughes Medical Institute, Ann Arbor, MI, USA.
Mehra R; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.; Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.; Pokaż więcej
Źródło:: Histopathology [Histopathology] 2020 May; Vol. 76 (6), pp. 875-887. Date of Electronic Publication: 2020 Apr 27.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Carcinoma, Renal Cell/*pathology
Kidney Neoplasms/*pathology
Adolescent ; Adult ; Age of Onset ; Child ; Female ; Humans ; Male ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Liquid biopsy: Where did it come from, what is it, and where is it going?
Autorzy:: Morgan TM; Department of Urology, University of Michigan, Ann Arbor, MI, USA.; Pokaż więcej
Źródło:: Investigative and clinical urology [Investig Clin Urol] 2019 May; Vol. 60 (3), pp. 139-141. Date of Electronic Publication: 2019 Apr 29.
Typ publikacji:: Editorial
MeSH Terms:: Liquid Biopsy*/methods
Liquid Biopsy*/trends
Humans ; Neoplastic Cells, Circulating

Opinia redakcyjna

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
Autorzy:: Kaye DR; Dow Division of Health Services Research, University of Michigan, Ann Arbor, MI, USA.; University of Michigan, Ann Arbor, MI, USA.
Qi J; Dow Division of Health Services Research, University of Michigan, Ann Arbor, MI, USA.
Morgan TM; University of Michigan, Ann Arbor, MI, USA.
Linsell S; Dow Division of Health Services Research, University of Michigan, Ann Arbor, MI, USA.
Ginsburg KB; Department of Urology, Wayne State University, Detroit, MI, USA.
Lane BR; Spectrum Health Urology, Grand Rapids, MI, USA.
Montie JE; Dow Division of Health Services Research, University of Michigan, Ann Arbor, MI, USA.; University of Michigan, Ann Arbor, MI, USA.
Cher ML; Department of Urology, Wayne State University, Detroit, MI, USA.
Miller DC; Dow Division of Health Services Research, University of Michigan, Ann Arbor, MI, USA.; University of Michigan, Ann Arbor, MI, USA.; Pokaż więcej
Corporate Authors:: Michigan Urological Surgery Improvement Collaborative
Źródło:: BJU international [BJU Int] 2019 May; Vol. 123 (5), pp. 846-853. Date of Electronic Publication: 2018 Oct 15.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Image-Guided Biopsy*
Prostatectomy*/statistics & numerical data
Watchful Waiting*
Neoplasm Grading/*methods
Prostate/*pathology
Prostatic Neoplasms/*pathology
Adult ; Aged ; Clinical Decision-Making ; Diffusion Magnetic Resonance Imaging ; Digital Rectal Examination ; Humans ; Male ; Middle Aged ; Patient Selection ; Prospective Studies ; Prostatic Neoplasms/diagnostic imaging

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Erectile function after stereotactic body radiotherapy for localized prostate cancer.
Autorzy:: Dess RT; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Hartman HE; Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
Aghdam N; Department of Radiation Oncology, Georgetown University, Washington, DC, USA.
Jackson WC; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Soni PD; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Abugharib AE; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Suy S; Department of Radiation Oncology, Georgetown University, Washington, DC, USA.
Desai NB; Department of Radiation Oncology, University of Texas Southwestern, Dallas, TX, USA.
Zumsteg ZS; Department of Radiation Oncology, Cedars-Sinai, Los Angeles, CA, USA.
Mehra R; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Morgan TM; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Feng FY; Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Hamstra DA; Department of Radiation Oncology, Beaumont Health System, Dearborn, MI, USA.
Schipper MJ; Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
Collins SP; Department of Radiation Oncology, Georgetown University, Washington, DC, USA.
Spratt DE; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.; Pokaż więcej
Źródło:: BJU international [BJU Int] 2018 Jan; Vol. 121 (1), pp. 61-68. Date of Electronic Publication: 2017 Aug 17.
Typ publikacji:: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Adenocarcinoma/*radiotherapy
Erectile Dysfunction/*etiology
Prostatic Neoplasms/*radiotherapy
Radiosurgery/*methods
Academic Medical Centers ; Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Aged ; Analysis of Variance ; Biopsy, Needle ; Brachytherapy/adverse effects ; Brachytherapy/methods ; Cohort Studies ; Disease-Free Survival ; Erectile Dysfunction/physiopathology ; Follow-Up Studies ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Multivariate Analysis ; Neoplasm Invasiveness/pathology ; Neoplasm Staging ; Predictive Value of Tests ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/pathology ; Radiosurgery/adverse effects ; Radiotherapy Dosage ; Retrospective Studies ; Risk Assessment ; Survival Analysis ; Time Factors ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Estimating the Optimal Personalized Treatment Strategy Based on Selected Variables to Prolong Survival via Random Survival Forest with Weighted Bootstrap.
Autorzy:: Shen J; a Department of Population Health Sciences , University of Utah School of Medicine , Salt Lake City , UT , USA.
Wang L; b Department of Biostatistics , University of Michigan , Ann Arbor , MI , USA.
Daignault S; b Department of Biostatistics , University of Michigan , Ann Arbor , MI , USA.
Spratt DE; c Department of Radiation Oncology , University of Michigan , Ann Arbor , MI , USA.
Morgan TM; d Department of Urology , University of Michigan , Ann Arbor , MI , USA.
Taylor JMG; b Department of Biostatistics , University of Michigan , Ann Arbor , MI , USA.; Pokaż więcej
Źródło:: Journal of biopharmaceutical statistics [J Biopharm Stat] 2018; Vol. 28 (2), pp. 362-381. Date of Electronic Publication: 2017 Oct 25.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:: Models, Statistical*
Survival Analysis*
Computer Simulation/*statistics & numerical data
Observational Studies as Topic/*statistics & numerical data
Precision Medicine/*methods
Prostatic Neoplasms/*mortality
Humans ; Male ; Precision Medicine/statistics & numerical data ; Probability ; Prostatic Neoplasms/drug therapy ; Research Design/statistics & numerical data ; Statistics, Nonparametric ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study.
Autorzy:: Jackson WC; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Desai NB; Department of Radiation Oncology, University of Texas Southwestern, Dallas, TX, USA.
Abugharib AE; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Tumati V; Department of Radiation Oncology, University of Texas Southwestern, Dallas, TX, USA.
Dess RT; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Lee JY; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Zhao SG; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Soliman M; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Folkert M; Department of Radiation Oncology, University of Texas Southwestern, Dallas, TX, USA.
Laine A; Department of Radiation Oncology, University of Texas Southwestern, Dallas, TX, USA.
Hannan R; Department of Radiation Oncology, University of Texas Southwestern, Dallas, TX, USA.
Zumsteg ZS; Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Sandler H; Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Hamstra DA; The Texas Center for Proton Therapy, Irving, TX, USA.
Montgomery JS; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Miller DC; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Kozminski MA; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Hollenbeck BK; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Hearn JW; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Palapattu G; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Tomlins SA; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Mehra R; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Morgan TM; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Feng FY; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.; Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Spratt DE; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.; Pokaż więcej
Źródło:: BJU international [BJU Int] 2017 Sep; Vol. 120 (3), pp. 351-357. Date of Electronic Publication: 2017 Feb 26.
Typ publikacji:: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Neoplasm Recurrence, Local/*epidemiology
Prostatectomy/*statistics & numerical data
Prostatic Neoplasms/*pathology
Prostatic Neoplasms/*therapy
Aged ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/epidemiology ; Retrospective Studies ; Salvage Therapy ; Treatment Failure

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Independent surgical validation of the new prostate cancer grade-grouping system.
Autorzy:: Spratt DE; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA. .
Cole AI; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Palapattu GS; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Weizer AZ; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Jackson WC; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Montgomery JS; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Dess RT; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Zhao SG; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Lee JY; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Wu A; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Kunju LP; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Talmich E; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Miller DC; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Hollenbeck BK; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Tomlins SA; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Feng FY; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Mehra R; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Morgan TM; Department of Urology, University of Michigan, Ann Arbor, MI, USA.; Pokaż więcej
Źródło:: BJU international [BJU Int] 2016 Nov; Vol. 118 (5), pp. 763-769. Date of Electronic Publication: 2016 Apr 19.
Typ publikacji:: Journal Article; Validation Study
MeSH Terms:: Prostatectomy*/methods
Prostatic Neoplasms/*pathology
Prostatic Neoplasms/*surgery
Adult ; Aged ; Aged, 80 and over ; Biopsy ; Disease-Free Survival ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples.
Autorzy:: Gogoi P; Celsee Diagnostics, 46701 Commerce Center Drive, Plymouth, Michigan, United States of America.
Sepehri S; Celsee Diagnostics, 46701 Commerce Center Drive, Plymouth, Michigan, United States of America.
Zhou Y; Celsee Diagnostics, 46701 Commerce Center Drive, Plymouth, Michigan, United States of America.
Gorin MA; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Paolillo C; Sidney Kimmel Cancer Center, Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America.; Laboratory of Molecular Biology, Department of Laboratory Medicine, University Hospital 'A. Gemelli', Rome, Italy.
Capoluongo E; Laboratory of Molecular Biology, Department of Laboratory Medicine, University Hospital 'A. Gemelli', Rome, Italy.
Gleason K; Celsee Diagnostics, 46701 Commerce Center Drive, Plymouth, Michigan, United States of America.
Payne A; Celsee Diagnostics, 46701 Commerce Center Drive, Plymouth, Michigan, United States of America.
Boniface B; Celsee Diagnostics, 46701 Commerce Center Drive, Plymouth, Michigan, United States of America.
Cristofanilli M; Division of Hematology/Oncology, Robert Lurie Cancer Center, Northwestern University, Chicago, Illinois, United States of America.
Morgan TM; Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, United States of America.
Fortina P; Sidney Kimmel Cancer Center, Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America.; Department of Molecular Medicine, University of Rome 'Sapienza', Rome, Italy.
Pienta KJ; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Handique K; Celsee Diagnostics, 46701 Commerce Center Drive, Plymouth, Michigan, United States of America.
Wang Y; Celsee Diagnostics, 46701 Commerce Center Drive, Plymouth, Michigan, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2016 Jan 25; Vol. 11 (1), pp. e0147400. Date of Electronic Publication: 2016 Jan 25 (Print Publication: 2016).
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:: Automation*
Lab-On-A-Chip Devices*
Neoplastic Cells, Circulating*
Breast Neoplasms/blood ; Colorectal Neoplasms/blood ; Female ; Humans ; In Situ Hybridization, Fluorescence ; Male ; Prostatic Neoplasms/blood

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy.
Autorzy:: Corcoran AT; Department of Urology, SUNY Stony Brook Medical Center, Stony Brook, NY, USA.
Kaffenberger SD; Department of Urology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Clark PE; Department of Urology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Walton J; Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA.
Handorf E; Biostatistics & Bioinformatics Facility, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA.
Piotrowski Z; Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA.
Tomaszewski JJ; Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA.
Ginzburg S; Department of Urology, Einstein Healthcare Network/Urologic Institute of Southeastern Pennsylvania, Philadelphia, PA, USA.
Mehrazin R; Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA.
Plimack E; Medical Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA.
Chen DY; Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA.
Smaldone MC; Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA.
Uzzo RG; Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA.
Morgan TM; Department of Urology, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Kutikov A; Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA.; Pokaż więcej
Źródło:: BJU international [BJU Int] 2015 Sep; Vol. 116 (3), pp. 351-7. Date of Electronic Publication: 2014 Dec 15.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:: Hypoalbuminemia/*mortality
Nephrectomy/*mortality
Nephrectomy/*statistics & numerical data
Aged ; Aged, 80 and over ; Carcinoma, Renal Cell/complications ; Carcinoma, Renal Cell/epidemiology ; Carcinoma, Renal Cell/mortality ; Carcinoma, Renal Cell/surgery ; Female ; Humans ; Hypoalbuminemia/complications ; Hypoalbuminemia/epidemiology ; Kidney Neoplasms/complications ; Kidney Neoplasms/epidemiology ; Kidney Neoplasms/mortality ; Kidney Neoplasms/surgery ; Male ; Middle Aged ; Prospective Studies ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy.
Autorzy:: Ark JT; Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Keegan KA
Barocas DA
Morgan TM
Resnick MJ
You C
Cookson MS
Penson DF
Davis R
Clark PE
Smith JA Jr
Chang SS; Pokaż więcej
Źródło:: BJU international [BJU Int] 2014 Jun; Vol. 113 (6), pp. 894-9. Date of Electronic Publication: 2014 Apr 03.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
MeSH Terms:: Carcinoma, Transitional Cell/*pathology
Urinary Bladder Neoplasms/*pathology
Aged ; Carcinoma, Transitional Cell/surgery ; Cystectomy ; Humans ; Neoplasm Staging/statistics & numerical data ; Retrospective Studies ; Risk Factors ; Urinary Bladder Neoplasms/surgery

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Morgan, Todd M."" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język